Targacept to discontinue TC-5214 overactive bladder program
Targacept announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive bladder. The high dose of TC-5214 demonstrated mixed results on co-primary endpoints and an improvement that did not reach statistical significance on episodes of urinary incontinence. July 29, 2014